Truist Financial Cuts Boston Scientific (NYSE:BSX) Price Target to $90.00

Boston Scientific (NYSE:BSX) had its price target lowered by Truist Financial from $92.00 to $90.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price points to a potential upside of 38.63% from the company’s previous close.

Several other equities analysts have also recently weighed in on BSX. National Bank Financial set a $115.00 price target on Boston Scientific in a report on Monday, February 2nd. Robert W. Baird cut their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Raymond James Financial restated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Jefferies Financial Group restated a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Finally, Evercore cut their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Boston Scientific Stock Performance

NYSE:BSX opened at $64.92 on Wednesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific has a 12-month low of $60.59 and a 12-month high of $109.50. The stock has a 50-day moving average price of $70.34 and a 200 day moving average price of $87.52. The stock has a market capitalization of $96.49 billion, a P/E ratio of 33.44, a P/E/G ratio of 0.98 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm’s revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors have recently modified their holdings of BSX. Norges Bank bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $2,199,395,000. Parnassus Investments LLC lifted its stake in shares of Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after purchasing an additional 6,868,459 shares during the last quarter. Egerton Capital UK LLP lifted its stake in shares of Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Maverick Capital Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $280,735,000. Finally, Jennison Associates LLC lifted its stake in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citi reiterates a Buy rating on BSX, keeping conviction in the name while lowering its price target from $98 to $87 — a signal that some analysts still see upside despite recent weakness. Citi Reiterates Buy Rating for Boston Scientific
• Positive Sentiment: Market commentary noted a recent intraday rise (but underperformance vs. the broader market), indicating some short-term buying interest amid mixed sentiment. Boston Scientific Corp. stock rises Tuesday, still underperforms market
• Positive Sentiment: Analysts and research pieces highlight BSX’s history of earnings beats and say the company has the profile to potentially beat the upcoming report — a catalyst that could support the stock if results and guidance are strong. Will Boston Scientific (BSX) Beat Estimates Again?
• Neutral Sentiment: Boston Scientific is expected to announce quarterly results imminently; the report and management commentary on procedure volumes and guidance will likely drive short-term price action. Boston Scientific Expected to Announce Earnings
• Negative Sentiment: Numerous law firms have filed or solicited investors for a securities-class-action alleging BSX and certain executives misrepresented U.S. electrophysiology demand/volume trends for a defined class period; the filings highlight potential legal, financial and reputational risk and include upcoming May 4 deadlines for lead-plaintiff motions. BSX Investor Alert: Securities Fraud Lawsuit – Levi & Korsinsky
• Negative Sentiment: Multiple other firms (Pomerantz, Rosen, Faruqi, Portnoy, etc.) have issued investor alerts and lawsuit notices, reinforcing media attention and the risk of continued selling pressure until legal exposure and management disclosures are clarified. Pomerantz Investor Alert

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.